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Abstract: Topical ophthalmologic treatments have been facing great challenges with main limitations
of low drug bioavailability, due to highly integrative defense mechanisms of the eye. This study
rationally devised strategies to increase drug bioavailability by increasing ocular surface residence
time of drug-loaded nanoliposomes dispersed within thermo-sensitive hydrogels (Pluronic F-127).
Alternatively, we utilized sub-conjunctival injections as a depot technique to localize nanoliposomes.
Senicapoc was encapsulated and sustainably released from free nanoliposomes and hydrogels
formulations in vitro. Residence time increased up to 12-fold (60 min) with 24% hydrogel
formulations, as compared to 5 min for free liposomes, which was observed in the eyes of
Sprague-Dawley rats using fluorescence measurements. Pharmacokinetic results obtained from
flushed tears, also showed that the hydrogels had greater drug retention capabilities to that of topical
viscous solutions for up to 60 min. Senicapoc also remained quantifiable within sub-conjunctival
tissues for up to 24 h post-injection.
Keywords: liposomes; senicapoc; ocular; hydrogel
1. Introduction
Revolutionary approaches to drug delivery systems in the treatment of ocular diseases have
rapidly emerged over the past decades. In general, the treatment of ocular surface disease relies
on topical administration of drugs. In contrast, the treatment of intraocular disease largely depends
on diffusion of drugs across the cornea to reach the anterior and posterior segments of the eye.
Topical eye drops, though convenient and with high patient compliance, suffer low bioavailability
due to washouts by static and dynamic defense mechanisms of the eye. Less than 5% of topically
administered drugs reach the anterior segment and an even smaller fraction reaches the posterior
chamber [1]. This suggests that dynamic clearance of drugs occurs primarily via tears or at the ocular
surface. Treatment of ocular surface diseases have also faced many challenges over the decades either
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due to poor treatment efficacies of topical eye drops or poor acceptability of the patients due to
more invasive routes of administration [1–3]. Commercially available free drug topical eye drops are
typically prepared in high concentrations to achieve therapeutic dosages [4], but they still require
frequent administration, and in some occasions induce toxicity due to fluctuating doses of drug [5].
Other common problems include drug spiking dosages and efficacy crashes [1].
New drug delivery strategies have been developed to prolong the bioavailability of
pharmaceutical drugs at the ocular surface. These include devices such as the corneal shield [2,6],
contact lenses [3,7–9], nano-particulate systems [10–18], and in situ hydrogels [19–23]. Corneal shield
and drug eluting contact lenses were developed to provide more controlled and sustained release of
drugs when in contact with the tear fluid. Nano-particulates and vesicular systems were primarily
developed to overcome challenges related to poor solubility of non-polar drugs, duration of drug
delivery [10,11,16–18], as well as targeting to specific sites [12,15].
For example, corneal shields are made of collagen derived from porcine or bovine origins and are
synthetically manufactured to undergo dissolution after a specific amount of time [6]. Collagen being
a major component of physiological systems is biocompatible and bioresorbable, making it a suitable
bio-device for drug delivery and wound healing. Corneal shields absorb tear fluids upon application
into the eye, softening into a pliable film that conforms to the ocular surface resulting in optimal surface
interaction with sustained drug release profiles based on largely bulk dissolution and diffusion [1].
Further developments by crosslinking were made to corneal shields to increase the dissolution time,
hence allowing the bio-device to act as a depot for sustained release via diffusion [2]. However,
a major drawback of commercially available corneal shields lies in its degree of opacity as compared
to contact lenses [2]. Unlike corneal shields, contact lenses are cross-linked transparent hydrogels
that do not undergo dissolution. Made of biocompatible polymers (e.g., poly (methyl methacrylate)
(PMMA), hydroxyethylmethacrylic acid (HEMA), silicone), drug-eluting contact lenses are hydrophilic
hydrogels that absorb water and swell for the exchange of small polar molecules, which facilitates
the sustained release of drugs by diffusion [3,7]. To enable non-polar drugs to be loaded into gels,
they could be first encapsulated within micro emulsions [7], liposomes [8], and even nanoparticles [9]
prior to suspension within contact lens matrices [3]. Although contact lenses have been well accepted
for the purpose of corrective vision, they have drawbacks due to deprivation of epithelial oxygen
density to the cornea, reducing tear film stability, and potentially increasing the risk of ocular surface
microbial infections.
In situ gel formulations for pharmaceutical applications has also garner its fair share of attention
over the past decade. These formulations are typically synthesized to undergo aqueous-based
sol-gel transition above physiological temperatures to form physically cross-linked gel-like matrices.
Temperature transitions of these formulations in aqueous solutions are related to the miscibility gap
in their respective temperature-composition diagram which corresponds to either a lower critical
solution temperature (LCST) [19–23] or upper critical solution temperature (UCST). Such formulations
are also particularly of interest to ocular surface treatments since they can be administered as eye
drops, and after instillation, can form physically cross-linked depots within the eye to increase
residence time and hence therapeutic bioavailability [21,22]. Some commonly known thermo-sensitive
polymers used for biological applications are polyxamers, poly-(N-isopropylacrylamide), poly-(vinyl
alcohol), and methylcellulose. Co-polymers consisting of thermo-sensitive and pH sensitive polymers
(e.g., Carbopol) are also often added in combination to increase gel strength and achieve suitable
consistencies in texture [23]. In the gel state, in situ hydrogels swell in the presence of fluid, resulting
in extended retention time, hence improving drug bioavailability.
As a delivery system for the ocular surface, liposomes have several advantages. They are
biocompatible [15,24] because they are typically made of phospholipids resembling mammalian
cell membranes. Protective mammalian surfactants that are secreted at air-liquid interfaces line
the pulmonary tract and the ocular surface, as well many other parts of the body to providing
lubrication. Dipalmitoylphosphatidylcholine (DPPC), more commonly known as lecithin, is a major
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lipid component found in these surfactants. They are fully biodegradable [14,17,24], relatively
non-toxic, and promote intracellular uptake [17]. It has been reported that conjugation with hydrophilic
polyethylene glycol can help to reduce uptake by macrophages [15,16,25]. Apart from surface
modifications, it has also been reported that the increase in physiological circulations time has also
been attributed greatly to the decreasing in liposomal size, which is resulted from the enhanced
evasion of liposomes from the mononuclear phagocytic system (MPS) [16,26]. A liposome is made up
of an aqueous core where hydrophilic drugs can be encapsulated, and surrounded by a non-polar
bilayer, where hydrophobic drugs can be associated, making it possible to incorporate multiple
payloads within each vesicle. Liposomes can also be easily manipulated to achieve monodispersity
from a range of various sizes between 80 nm to 10 µm [15]. Nanoliposomes with size below 100 nm
exhibit reduced light scattering and provides adequate transparency, making it suitable for ocular
applications [18]. Although drug concentrations have been reported in both anterior and posterior
segments of the eye after sub-conjunctiva administration [4,5,10,27], however these finding were not
a representation of potential treatments of ocular surface disease, apart from one other article that
describes sub-conjunctival injections of nanoliposomes as a potential treatment of diseases that targets
the ocular surface [28].
To maintain high patient compliance while achieving therapeutic efficacy, we propose the
use of drug-loaded nanoliposomes dispersed within thermo-sensitive hydrogels (Pluronic F-127),
via a topically applicable hydrogel formulation or a minimally invasive sub-conjunctival injection
to increase the residence time and bioavailability of ocular therapeutics. Here, we also describe the
encapsulation of a specific inhibitor of the calcium-activated potassium channel, KCa3.1, for delivery
to the ocular surface. KCa3.1 channels are validated targets for immunomodulation and in reducing
conjunctiva and corneal [29] as well as other TGF-β induced fibrosis [29,30]. KCa3.1 inhibitors are
reported to be effective in the treatment of corneal alkali burn in a mouse model [31]. Senicapoc,
the drug chosen for our study, has also been shown to be biologically safe during its advancements
in human trials [32,33]. Pluronic F-127 is a polymer that displays thermo-sensitive gelation and
is concentration dependent. It portrays a lower critical solution temperature dependence that is
only exhibited with a minimum of 16 wt% solids at a fusion point on the phase diagram [34].
Its biocompatibility [35,36], composition variability, low toxicity [37], and spontaneous formation
of transparent hydrogels at physiological temperatures makes it a suitable choice of ophthalmic
applications [23,35]. Pluronic F-127 hydrogels has also been reported to form matrixes that stabiles
liposomes [38], as well as reduce drug degradation [39], hence enhancing bioavailability. In this study,
we prepared Senicapoc-loaded liposomes within a thermo-sensitive hydrogel matrix of different
concentrations of Pluronic F-127. Our primary objective was to prolong the release, and increase
the bioavailability of Senicapoc within the ocular surface following patient compliant topical
administration of hydrogel liposomal formulations. In addition to eye drops, we also considered
an alternative use of sub-conjunctival injection, which potentially serves to bypass the tight junctions
of the corneal epithelium [40,41]. The widely known inefficiency of topical therapeutics attributed to
challenges of low penetrability of the corneal epithelium can be overcome by sub-conjunctiva injections
which serve as an alternative yet independent route of trans-sclera penetration [4,5] and to prolong the
potential treatment of ocular surface disease [4,5,28,42].
2. Results
2.1. In Vitro Size and Drug Loading Stability of Senicapoc-Loaded Liposomes
In this study, we monitored the liposome size and drug loading (formulation stability) at storage
condition of 4 ◦C to determine its potential shelf-life over a period of 28 days (Figure 1). At endpoint,
it was observed that 20 mM Senicapoc-loaded DPPC liposomes had no significant changes in its size
with an average of 91.3± 1.2 nm (Figure 2) over a period of 28 days as compared to the initial fabricated
size of 90.0 ± 0.5 nm (n = 3). Extruded Senicapoc-loaded Liposomes were fabricated consistently with
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an initial drug loading of 7.73 ± 0.23 mol % (n = 3). The liposomal formulation maintained a drug
loading capacity of 93.0 ± 1.5% of the initial drug content after a period of 28 day storage at 4 ◦C.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 17 
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2.2. In Vitro Release of Senicapoc-Loaded Liposomes
The cumulative drug release of Senicapoc from DPPC liposomes (Figure 3) was observed over
a period of 28 days before achieving a cumulative released amount of 86.3± 3.9%. Therapeutic sages
of 1 µM of Senicapoc, est blished for the suppression of 90% naive and central memo y T cells [43–48]
had been sustain bly achieved initially within 5 days, and possibly up to 7 days before an additional
instill tion wa required.
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Figure 3. (A) Cumulative percentage release and (B) daily mass release of Senicapoc from drug-loaded
liposomal formulation over a period of 28 days at 37 ◦C. All data are reported as mean ± SD
of duplicates.
2.3. In Vitro Release of Senicapoc-Loaded Liposomal Hydrogel Formulation
The release of Senicapoc from the Senicapoc-loaded liposomal dispersion within an 18% hydrogel
(Figure 4) also xhibited sustained r lease profile ov r a eriod of 28 days before achieving
a cumulative rel ase of 81.2 ± 1.7%. For the first day, Senicapoc mass release was not significa tly
different (p = 0.67) from that of the lip somal hy rogel dispersion formulation as c mpared to the
free liposomal formulation (Figure 3). Subsequent release from day 2 to day 4 and day 13 (p < 0.05)
were significantly lower, while days 5 and 7 (0.05 < p < 0.07) and day 6 and 14 (p = 0.19 and p = 0.13
respectively) as well as the rest of the time points (p > 0.2), however showed no significant difference
between the liposomal hydrogel dispersion formulation as compared to the formulation without the
hydrogel matrix.
Int. J. ol. Sci. 2018, 19, x FOR PEER REVIEW  5 of 17 
 
 
Figure 3. (A) Cumulative percentage release and (B) daily mass release of Senicapoc from drug-
loaded liposomal formulation over a period of 28 days at 37 °C. All data are reported as mean ± SD 
of duplicates. 
2.3. In Vitro Release of Senicapoc-Loaded Liposomal Hydrogel Formulation 
The release of Senicapoc from the Senicapoc-loaded liposomal dispersion within an 18% 
hydrogel (Figure 4) also exhibited a sustained release profile over a period of 28 days before achieving 
a cumulative release of 81.2 ± 1.7%. For the first day, Senicapoc mass release was not significantly 
different (p = 0.67) from that of the liposomal hydrogel dispersion formulation as compared to the 
free liposomal formulation (Figure 3). Subsequent release from day 2 to day 4 and day 13 (p < 0.05) 
were significantly lower, while days 5 and 7 (0.05 < p < 0.07) and day 6 and 14 (p = 0.19 and p = 0.13 
respectively) as well as the rest of the time points (p > 0.2), however showed no significant difference 
between the liposomal hydrogel dispersion formulation as compared to the formulation without the 
hydrogel matrix. 
(A) (B) 
Figure 4. (A) Cumulative percentage release and (B) daily mass release of Senicapoc from drug-
loaded liposomes dispersed in 18% hydrogel formulation over a period of 28 days at 37 °C. All data 
are reported as mean ± SD of duplicates. 
2.4. In Vivo Residence of Hydrogel on Ocular Surface of Sprague Dawley Rats 
The fluorescein-tagged free liposomes, viscous formulation and gel formulation were applied 
onto eyes of anesthetized rats respectively to determine the retention time on the ocular surface. To 
Figure 4. (A) Cumulative percentage release and (B) daily mass release of Senicapoc from drug-loaded
liposomes dispersed in 18% hydrogel formulation over a period of 28 days at 37 ◦C. All data are
reported as mean ± SD of duplicates.
Int. J. Mol. Sci. 2018, 19, 2977 6 of 17
2.4. In Vivo Residence of Hydrogel on Ocular Surface of Sprague Dawley Rats
The fluorescein-tagged free liposomes, viscous formulation and gel formulation were applied
onto eyes of anesthetized rats respectively to determine the retention time on the ocular surface.
To compensate for the dilution of hydrogel formulation by tears present in the rat eyes, 24% hydrogel
formulations were prepared instead of 18% hydrogel formulations. This consideration was to prevent
the excessive dilution of the gel formulation to drop below the critical solution composition for gelation
at physiological temperature of 37 ◦C. Fluorescein signals from these formulations were recorded by
the Micron IV imaging system under cobalt blue filter at different time points (Figure 5). Since cobalt
blue light lacks the intensity to generate auto-fluorescence from eye tissues, and in the absence of
fluorescein, all baseline images taken appeared black with no difference between the rats (not shown
in Figure 5).
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  6 of 17 
 
compensat  for the dilutio  of hydrogel formulation by tears present in the rat ey s, 24% hydrogel 
formulations were prepared instead of 18% hy r gel formulations. This c nsiderati n was to prevent 
the excessive dilution of the gel formulation to drop below the critical solution composition for 
gelation at physiological temperature of 37 °C. Fluorescein signals from these formulations were 
recorded by the Micron IV imaging system under cobalt blue filter at different time points (Figure 5). 
Since cobalt blue light lacks the intensity to generate auto-fluorescence from eye tissues, and in the 
absence of fluorescein, all baseline images taken appeared black with no difference between the rats 
(not shown in Figure 5). 
 
Figure 5. Residence images (Micron IV Imaging) of free fluorescein-tagged liposomes and hydrogel 
formulations in eyes of anesthetized Sprague-Dawley rats. Two rats were used for each formulation. 
Figure 5. Residence images (Micron IV Imaging) of free fluorescein-tagged liposomes and hydrogel
formulations in eyes of anesthetized Sprague-Dawley rats. Two rats were used for each formulation.
Int. J. Mol. Sci. 2018, 19, 2977 7 of 17
As seen in Figure 5, the free liposomes could not be observed on rat ocular surfaces 5 min after
application, whereas the viscous formulation could be observed for up to 30 min, and the observed
retention of gel formulation was the longest at 60 min. During eye blinking, free liposome and viscous
formulations spread more rapidly on the ocular surface than the gel formulation, and thus were cleared
faster. The blinking of the rat’s eyes had a tendency to expel the excessive formulation, which explained
the observed fluorescence on the eyelids and the eyelashes for all formulations.
The retention time of viscous formulation and gel formulation on ocular surface of anesthetized
rat was also examined by fluorophotometry. As the scanning software of Fluorotron Master™ was
designed according to the human eye, the actual magnitude of the measurements for the rat eye
distances in the horizontal axis was not applicable for this purpose, but this did not affect the
interpretation of fluorescence signals in the vertical axis.
Although the clearance of foreign substances from ocular surface was dominant (>75% [1])
mainly through eye blinking and the nasolacrimal tear drainage system [4,5,10,14,28], however,
the consideration for drug penetration was not neglected. In Figure 6, the fluorescence signal of
the viscous formulation could be observed at the surface of the eye even after 60 min, in the
absence of blinking. It is also interesting to note that the fluorescence peak for gel formulation
shifted posteriorly towards the back of the eye within the initial 3 min after instillation and
eventually residing within the eye for up to 30 min in the study. Fluorescein has been widely used
as a fluorophore for labeling to study the distribution of liposomal vesicles biologically [49,50].
It is also commonly known for its ease of photo-bleaching. However, in this study, caution was
taken to ensure that exposure time of all fluorescein-labelled formulations after applications were kept
constant and away from excessive photo-excitation as a result of light exposure, hence eliminating
inconsistent photo-bleaching of formulations during measurements. Furthermore, as the hydrophilic
carboxyfluorescein is chemically attached to the hydrophilic head of the lipid as used in this study,
the labelled liposomes that were subsequently fabricated remained amphiphatic. Lee J. et al. [49] also
reported that carboxyfluorescein-conjugated PEGylated DMPC-based liposomes exhibited increased
penetration of the retina layers as compared to the same liposomes with carboxyfluorescin loaded in the
aqueous core, which did not show any sign of facilitated penetration. Therefore, the carboxyfluorescein-
labelled liposomal formulation described in this study may have been likely to exert an influence
on the penetration of the ocular surface as shown in Figure 6B. Importantly, the penetration of the
fluorescence-labelled liposomes can be attributed to the extended residence of the gel formulation at
the ocular surface (Figure 5), which was comparably not observed for the viscous formulation.
2.5. In Vivo Pharmacokinetic Analysis of Eye-Flush Tears
The topical instillation of 10 µL Senicapoc-loaded liposomal hydrogel formulations into the eyes
of Sprague-Dawley rats were well-tolerated with no significant sign of irritation or redness being
observed. Eye-flush tears were collected and analyzed as described in the materials and method
section. Figure 7 shows the higher concentrations of Senicapoc were present in the eye at all-time
points consistent with increased residence time provided by the 24% gel formulation (shown previously
in Figure 5). This has implications for improvement in therapeutic bioavailability of the drug compared
to drug associated with free liposomal eye drops.
2.6. In Vivo Pharmacokinetic Analysis of Sub-Conjunctival Injection
The delivery of nanoliposomes without gels via sub-conjunctiva injection was investigated as an
alternative measure to increase bioavailability to the ocular surface. It was found that Senicapoc from
the Senicapoc-loaded DPPC liposomes in the sub-conjunctiva tissues were detectable and quantifiable
up to 24 h (Figure 8), indicating a rapid but sustained delivery of Senicapoc, associated with a rapid
clearance rate. At 3-week time-point, the presence of Senicapoc was no longer detectable, and was
representative of a complete liberation from the injection site. This method of quantification performed
correlated indirectly to the combination of drug release kinetics and the migration of liposomes away
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from the injection depot, and were in alignment with the experimental findings of Natarajan et al. [51].
In another study performed by Natarajan et al., they also displayed pre-clinical efficacy of latanoprost
in glaucoma treatment (i.e., anterior diseases) beyond 90 days, after sub-conjunctiva injection of
latanoprost-loaded liposomes into rabbit eyes [52]. This further indicates the potential residence and
bioavailability of the therapeutic and the drug-loaded liposomes in the eye after their migration away
from the injection site.
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Several distributional pathways of the nanoparticles have been identified within the eye, including
nasolacrimal and lymphatic clearance routes via lymph nodes [28]. Feng et al. [28] found that
the internalization and distribution of their pRNA nanoparticles had different terminal locations
(conjunctiva, cornea, sclera, and retina), related to the shape and size of the nanoparticles, and
encouragingly, nanoparticles remained detectable by fluorescence up to 20 h. Another study that used
sub-conjunctiva injection of poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing brinzolamine
for glaucoma treatment showed positive efficacy data in the reduction of intraocular pressure
of up to 7 days after a single injection, which was attributed to the longer mean retention time
of the PLGA nanoparticles compared to eye drops [27]. Collectively, these data highly suggest
that minimally invasive sub-conjunctiva injections could reduce the distributional clearance of
Senicapoc-loaded liposomes within the eye, and could serve as depots for sustained release in treatment
of ocular diseases.
3. Discussion
In this study, we focus on nanoliposomal delivery systems for the treatment of ocular surface
diseases. We explored a novel engineered Senicapoc-loaded topical liposomal hydrogel eye drops as
a strategy to prolong corneal treatment efficacies, while we also explored the use of sub-conjunctiva
injection as an indirect treatment method to target ocular surface diseases. Senicapoc-loaded liposomes
were prepared in a thermo-sensitive hydrogel matrix of different concentrations of Pluronic F-127.
In vitro results show that Senicapoc can be released sustainably from DPPC liposomes regardless
of whether the liposomes are free or dispersed within a Pluronic F-127 hydrogel over an extended
period of 28 days. In vivo studies show that Pluronic F-127 hydrogel at 24 wt% concentration increases
the residence time of the nanoliposomes on the surface of the eye, also increases bioavailability and
supports the penetration of the nanoliposomes into the eye.
The greatest challenges faced by topical eye drops is commonly attributed to the corneal route
of penetration [4]. Since it is also widely reported that topical solutions are highly ineffective in
travelling to the posterior segment of the eye [4,10], the dominant residence of hydrogel formulation
which improves bioavailability of the therapeutic at the ocular surface and the anterior chamber.
It is an encouraging opportunity for the use in ocular surface treatments.
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In vitro experiments showed that free liposomal formulations achieved therapeutic dosages for the
initial 5 days while liposomal hydrogel formulation exhibited the same for its initial 3 days. The increase
in the viscosity of the formulation is attributed to the presence of physically cross-linked polymer
of Pluronic F-127 [35]. That could contribute to the slight deduction of initial release of Senicapoc
from hydrogel formulation. In vivo experiments shows the liposomal hydrogel formulation increases
residence time by up to 6-fold (viscous solution) and 12-fold (hydrogel) compared to free liposomal
formulation (Figure 5). Being a physically cross-linked hydrogel, Pluronic F-127 will eventually be
eliminated through the nasolacrimal pump as a results of the breakdown of the hydrogel by a mixture
of dilution by tear replenishment, erosion and degradation mechanism [37]. Furthermore, although
it shows a higher daily release amount from the liposomes group, the clearance of unprotected
liposomes can rapidly decrease the bioavailability of Senicapoc within the eye, as shown in Figure 5.
While the slightly lower daily release of Senicapoc from the hydrogel formulation, the residence of
the formulation is indeed prolonged much longer (up to 12 folds) based on the study performed in
Figure 5. Hence, the rapid clearance experienced from the liposomal formulation is more likely to
provide less bioavailability as compared to the hydrogel formulation, and the tendency for frequent
administration is more likely to be required for the free liposomal formulation instead. The extended
residence of the hydrogel formulation also delays clearance rates of the formulation at the ocular
surface, hence providing sufficient time for penetration of the liposomes into the eye as seen in the
results reported in Figure 6. This concept of prolonging the residence time on the ocular surface to
increase penetrable bioavailability can further be justified by literature, where it was reported that use
of Dexamethasone eye drops containing gamma-cyclodextrin-based nanogels may provide extended
time for penetration, as well as providing a sustained release of dexamethasone while avoiding drug
spikes [13]. Hence, these suggest a need to compromise between achieving a high initial therapeutic
dosage and a prolonged retention of drug, which was further shown with a pharmacokinetic study
using flushed tears (Figure 7). In a similar study performed by Hsiue et al. [21], drug and drug-loaded
nanoparticles entrapped within a hydrogel matrix of thermosensitive poly-N-isopropylacrylamide
exhibited prolong sustained effect compared to traditional ophthalmic eye drops in rabbits.
Due to static/dynamic drug clearance and defense mechanisms of the eye, reduced penetration
and rapid elimination of the bulk topically administered formulations [4], resulted in the significant
decrease in Senicapoc levels detectable in flushed tears over a period of 90 min in rats (Figure 7).
Static barriers such as tight junctions of the corneal epithelium also dominates by preventing
major penetration of drug molecules across the cornea [1,5,14]. In addition, dry eye disease is also
characterized as an ocular surface disorder [1], which produces its greatest effect when drugs reside on
the surface of the cornea. Hence, the quantitation of prolonged drug bioavailability in flushed tear
concentration would provide the best indication of such a treatment. As a result of increased viscosity,
hydrogel formulations were shown to significantly increase bioavailability, compared to a less viscous
formulation of Pluronic F-127 for up to 30 min. Therapeutic dosages were also achievable within
the eye for close to 60 min for hydrogel formulations, or six times longer than viscous formulations
(Figure 7). This would be expected to be much longer than what is attainable with currently available
free drug topical solutions. In vivo results reported by Hsiue et al. [21] have also shown that drug and
drug-loaded nanoparticles encapsulated within their hydrogel increased bioavailability 5-fold over
conventional eye drops, with resulting increase in efficacy. The results obtained are also consistent with
the general use of hydrogels as carrier matrices to prolong and sustain therapeutic drug delivery [1].
It is also exciting to note that the gentler gradient of the release profile exhibited by liposomal hydrogel
formulation (Figure 4) compared to the free liposomal formulation (Figure 3) reduces the spiking effect
and contributing to a more controlled daily drug release profile.
As a consideration, sub-conjunctiva injections have also been widely explored for ocular delivery
of therapeutics. This strategy is widely used to overcome the limitations posed by corneal route of
penetration, for the movement of therapeutics towards the back of the eye. However, although the
strategy of using sub-conjunctiva injection is mainly to target posterior eye pathologies, it has also
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been widely reported that drug concentrations can be detected in both anterior as well as posterior
chambers of the ocular globe [4,5,10,27,28]. In particular, the article reported by Feng L. et al. [28]
showed that after sub-conjunctiva injection, not only did their pRNA nanoparticles retain in the
conjunctiva tissues, but the migration of their pRNA nanoparticles could be found to be up taken by
the cells of the cornea and sclera. Hence, it was interesting to explore the trans-sclera route provided
by sub-conjunctival injection for the treatment of ocular surface diseases. Senicapoc-loaded liposomes
injected into the connective tissues within the sub-conjunctiva, can also provide a natural depot for
prolonging liposomal residence by weak hydrophobic epithelial–stromal interactions [24].
Figure 8 provides insights of the residual drug concentration left within the conjunctiva tissues
after 24 h, which indirectly provides correlational information to the rate of release from the liposomes,
as well as trans-sclera migration of the liposomes after sub-conjunctiva injection. The possible release
of drugs from the liposomes injected with the sub-conjunctiva tissues, as well as the possible migration
of nanoparticles that occurs within the eye as reported by Feng L. et al. [28], would likely correlate
to low detectability of Senicapoc within sub-conjuctiva tissues after 24 h (Figure 8). A limitation
experienced in this sub-conjunctiva injection study was the inability to collect sufficient tears for
analysis due to a combination of various factors, which includes the small volume of tear production,
as well as the reduced tear production of the rats during anesthetized states. The quantification of the
tear concentrations would have been useful in the comparison to tear concentration accumulated on
the ocular surface of the hydrogel formulation. Another limitation of the sub-conjunctival injection
experiment is that there was no time point between 1 and 24 h. While the rats were anesthetized
during sub-conjunctival injection, the individual rats woke up from 1 to 4 h post-anesthesia. However,
the conditions of the rat eyes were different during sleep and when awake. To compensate the
possible different effects of anesthesia on individual rats, we only harvested tissue 24 h after injection.
Nevertheless, articles reported by Natarajan J.V. et al. [51,52] on the sustained release of latanoprost,
a therapeutic for glaucoma, characterized for the treatment of high intra-ocular pressures in the anterior
chamber of rabbit eyes, from liposomal formulations showed sustained release of up to 50 days, and
subsequently 90 days in the following citations respectively [51,52]. Although the results reported by
Natarajan J.V. et al. [51,52] were based on in vivo efficacy studies, the results are, however, relatable
and can be used as a justification of the possible migration of the nanoliposomes by trans-sclera
route into the anterior chamber. This suggests a similar basis for the fabrication of Senicapoc-loaded
nanoliposomes to be used in sub-conjunctiva injection, for the potential treatment of diseases of the
ocular surface.
4. Materials and Methods
4.1. Materials
Senicapoc was a gift from Prof. Heike Wulff, University of California, Davis.
Dipalmitoylphosphatidylcholine (DPPC) and 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N-
(Carboxyfluorescein) were purchased from Avanti Polar Lipids (Abalaster, AL, USA). Whatmann
drain discs and polycarbonate membrane filters were purchased from GE Healthcare Life Sciences
(Freiburg, Germany). Chloroform (HPLC Grade) was purchased from Tedia Chemicals (Fairfield,
OH, USA). Acetonitrile and Methanol (LCMS Grades) were purchased from Fisher Scientific (Hampton,
NH, USA). Cellulose ester dialysis tubings (100 kDa MWCO) and tubing closures were obtained from
Spectrum Laboratories (Rancho Dominguez, CA, USA). Salts used to make Phosphate Buffered Saline
(PBS) includes sodium chloride (NaCl), potassium chloride (KCl), Di-sodium hydrogen phosphate
(Na2HPO4) and Potassium dihydrogen phosphate (KH2PO4) were all purchased from Sigma-Aldrich
(St. Louis, MO, USA). Zinc Sulphate Monohydrate salt for analytical processing was also purchased
from Sigma-Aldrich. Soft tissue homogenizing kits (CK14, 0.5 mL) used for tissue analysis were
purchased from Bertin-Instruments (Rockville, MD, USA).
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4.2. Preparation of Liposomal Suspension
4.2.1. Fluorescein-Tagged DPPC Liposomal Suspension
The 20 mM fluorescein-tagged DPPC liposomes were prepared by dissolving 11.4 mg (2 mM)
of 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N-(Carboxyfluorescein) and 66.1 mg (18 mM) of
DPPC lipids and chloroform: methanol with a 2:1 ratio in a round-bottom flask (RBF). The RBF was
secured to a rotary evaporator and held for 60 min within a 40 ◦C water bath for the rapid removal
of the organic solvents. A thin-layered film of the lipid mixture was eventually formed on the inner
surface of the round-bottomed flask. The spontaneous formation of multilaminar vesicles (MLVs) was
achieved upon rehydration with 5 mL of phosphate buffered saline (PBS, pH 7.4). The MLVs were
then subjected to extrusion using a 10 mL LIPEX extruder heated at 60 ◦C with a circulating water
bath and extruded with 5 cycles of 200 nm membrane filters followed by 10 cycles of 80 nm membrane
filter to form small unilaminar vesicles (SUVs). The loss of buffer through the extrusion process was
measured and reconstituted with PBS to 5 mL of final stock liposomal formulation. The stock liposomal
formulation was subsequently stored at 4 ◦C for future use.
4.2.2. Senicapoc-Loaded DPPC Liposomal Suspension
The 10 mol % Senicapoc-loaded DPPC liposomes were prepared by dissolving 3.2 mg of Senicapoc
and 73.4 mg (20 mM) of DPPC lipids in chloroform: methanol with a 2:1 ratio in a round-bottomed
flask (RBF). The subsequent steps for the preparation were identical to the fabrication methodology as
mentioned above in Section 4.2.1.
4.2.3. Pluronic F-127 Hydrogel Formulations
Senicapoc-loaded liposomes were subsequently loaded into Pluronic F-127 hydrogels by hydrating
160, 180, and 240 mg of Pluronic F-127 polymer with 1 mL of the final liposomal suspension and
dissolved overnight at 4 ◦C to form a 16% viscous solution, 18% and 24% formulation that was capable
of gelation in situ, respectively.
4.3. Size Measurements of Senicapoc-Loaded Liposomes
Measurement of liposome hydrodynamic size were performed using dynamic light scattering
(DLS). The experiment was conducted by suspending 10 µL of Senicapoc-loaded or Fluorescein-tagged
nanoliposomes in 1 mL of de-ionized (DI) water, within a cuvette. The resultant cuvette was then
placed in a Malvern Zetasizer System for measurement. All measurements were made in triplicates.
4.4. Drug Loading of Senicapoc-Loaded Liposomal Suspension
Drug loading of formulations were indirectly quantified by back calculation for the total extruded
volume of 5 mL, with a fractional volume (5 µL) measurement taken from the total extruded volume
of the liposomal suspension, and subsequently quantified by liquid-liquid extraction. Quantification
of fractional drug content was performed by lysing 5 µL of liposomes suspension with PBS and
acetonitrile to a final ratio of 2:8 respectively. Samples were filtered through a 0.22 µm regenerated
cellulose (RC) filter and subsequently analyzed using liquid chromatography mMass spectroscopy
(LCMS, Waters Corporation) with multiple reaction monitoring, through a BEH 1.7 µm C-18 column,
2.1 mm × 50 mm using an in situ mixed Isocratic mobile phase of 80% Acetonitrile + 0.1% Formic Acid
and 20% DI Water + 0.1% Formic Acid, at a flowrate of 0.25 mL/min. LCMS results were analyzed by
comparison to a pre-developed calibration curve. Lower limit of Detection (LoD) and lower limit of
Quantitation (LoQ) were determined at 0.5 ng/mL with the latter defined by signal to noise (S/N)
ratio value ≥20.
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4.5. In Vitro Stability of Senicapoc-Loaded Liposomal Suspension
Senicapoc-loaded liposomes were monitored for stability based on size and drug loading over
a period of 28 days. Samples from the stock liposomal formulation stored at 4 ◦C were periodically
considered for analysis. Characterization of liposome sizes by intensity were performed with dynamic
light scattering (DLS) measurements using Malvern Nano Zetasizer. Characterization for drug loading
at periodic time points were performed identically using the method as described above in Section 4.4.
4.6. In Vitro Release Studies of Senicapoc-Loaded Liposomes & Hydrogel Formulations
Sample volumes by mass, containing 121.5± 10.9 µg of Senicapoc, were dispensed into individual
dialysis tubing before being secured and placed submerged within wide-mouth bottles containing
30 mL of PBS each. The bottles were subsequently placed in a 37 ◦C incubator with a shaking speed of
50 rpm to mimic physiological eye conditions [27]. The release assays were also performed for 28 days
in triplicates to ensure consistency. Samples were aliquoted before being replaced on a daily basis with
fresh PBS to maintain sink conditions. Two hundred microliters of sample was mixed thoroughly with
800 µL acetonitrile and filtered before characterizing the quantity released using the LCMS method as
mentioned above.
4.7. In Vivo Study
4.7.1. Animals
Female Sprague-Dawley rats between 6–8 weeks old (InVivos, Singapore) were used in this
experiment. Animals were handled according to institutional guidelines and the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research. The study protocol was approved by
the Institutional Animal Care and Use Committee of SingHealth (2014/SHS/0983, approval date:
29 September 2014).
4.7.2. In Vivo Residence of Pluronic F-127 Hydrogel
Three rats were anesthetized with ketamine (75 mg/kg) and xylazine (10 mg/kg). Ten microliter
of fluorescein-tagged free liposome, viscous formulation (16%), and gel formulation (24%) were applied
into the conjunctival sac of the rat eyes. To determine the retention time of the fluorescein-tagged
liposome on ocular surface, rat eye was examined by fluorescein imaging and fluorophotometry.
Fluorescein imaging on the rat ocular surface was performed with Micron IV (Phoenix Research
labs, Pleasanton, CA, USA) platform with a cobalt blue filter. Rat eyes were imaged every 5 min,
and to prevent dessication of rat eyes, lids were passively blinked every 30 s between two examinations.
Fluorophotometry of the rat eye was carried out with Fluorotron Master™ (OcuMetrics, Mountain
View, CA, USA) with the rat lens. This equipment recorded the fluorescence signal along the visual axis
in the posterior to anterior direction of the eye. Before applying the fluorescent formulation, a baseline
measurement of the rat eye was obtained. After application of the formulation, the rat was held on
an adjustable stand and the cornea of rat eye was adjusted to face the lens. Eye was imaged every
3 min, without any blinking between scans. This is in consideration that rat eyes are very small with
an axial length of around 6 mm, hence passive blinking will change the position of the eye, and results
in the inconsistent scan readings.
4.7.3. In Vivo PK Analysis of Flushed Tears
The 10 µL of viscous formulation (16%) and gel formulation (24%) were applied, using standard
administration procedure for topical eyedrops [1,5,10], into the conjunctival sac of the right and left eye
of a rat respectively. The rat eyes were passively blinked every 30 s to prevent desiccation of the ocular
surface. Eye-flush tears were collected at 4 specific time points after 10, 30, 60 and 90 min. At each time
point, the 10 µL of PBS was instilled on rat cornea, the rat eye was passively blinked 3 times, and then
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10 µL of flush tears collected by a 10-µL capillary tube (Sigma-Aldrich, St. Louis, MO, USA) and stored
under −80 ◦C. Baseline eye-flush tears collected before formulation instillation was used as control.
Senicapoc in tear samples were quantified by mixing 1 µL of the tear sample with specific volumes of
PBS and acetonitrile to achieve a final ratio of 1:4 and subsequently analyzed using LCMS method as
described in Section 4.4.
4.7.4. In Vivo PK Analysis of Sub-Conjunctival Injection
The 18 rats were anesthetized prior to the injection of Senicapoc nanoliposome (5 µL) into
the subconjunctiva of right eye. Left eye were injected with the same volume of PBS as control.
Subconjunctiva injection was performed by gently pulling conjunctiva from the sclera with a pair of
forceps, and nanoliposome or PBS was injected into the superior subconjunctival region using a 50 µL
Hamilton syringe with a 30G needle. Injected rats were randomly divided into 3 groups according to
the study plan as shown in Table 1.
Table 1. Study Plan for in vivo PK study of Sub-conjunctiva Injection.
Study Plan
Sample Formulation 8.5 mol % Senicapoc-Loaded Liposomal Formulation
Timepoints Baseline/Calibration 1 h 24 h 3 weeks
Number of Rats 3 6 6 6
Selection of Eye Left Right Left Right Left Right Left Right
Type of Eye Drop - - PBS Control Sample PBS Control Sample PBS Control Sample
Conjunctival tissues covering the eye globe from limbus to fornix were harvested from both eyes
at 1 h, 24 h and 3 weeks after injection. Harvested tissues were stored at −80 ◦C until use. Conjunctival
tissues from another 3 control rats were used for LC-MS baseline and calibration. Senicapoc in
conjunctival tissues were extracted after tissue homogenization with PBS and acetonitrile in a ratio
of 1:4 at 10,000 rpm on 30 s “on” followed by 30 s “off” Interval for 2 cycles, before quantification by
the LC-MS.
4.8. Statistical Analysis
Results are reported as mean ± standard deviation. Parametric two-tailed independent t-test
analysis were used to compare means between experimental groups and a p-value of <0.05 was
considered statistically significant.
5. Conclusions
In this study, we discuss two potential strategies to administer our novel formulations of
Senicapoc-loaded hydrogel as a topical eye drop, and Senicapoc-loaded liposomes as a sub-conjunctiva
injectable, as treatment strategies for the targeting of ocular surface diseases. Senicapoc-loaded
liposomes were prepared in a thermo-sensitive hydrogel matrix of Pluronic F-127. In vitro results
show that Senicapoc can be released sustainably from selected DPPC liposomes over an extended
period of 28 days. In vivo studies show that Pluronic F-127 hydrogel at 24 wt% concentration increases
the residence time of the nanoliposomes on the surface of the eye, increases bioavailability, and
also supports the penetration of the nanoliposomes into the eye. Alternatively, Senicapoc can be
administered via sub-conjunctival injection, the tissues PK remains for up to 24 h post-injection.
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